Generated Narrative: Citation

url: https://fevir.net/resources/Citation/179637

identifier: FEvIR Object Identifier/179637, https://pubmed.ncbi.nlm.nih.gov/18508207

version: 1.0.0-ballot

title: 18508207 A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal.

status: active

date: 2024-04-27 20:42:39+0000

publisher: HL7 International / Clinical Decision Support

contact: HL7 International / Clinical Decision Support: http://www.hl7.org/Special/committees/dss

description: This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.

UseContexts

jurisdiction: World (m49.htm#001)

copyright: https://creativecommons.org/licenses/by-nc-sa/4.0/

approvalDate: 2008-12-16

lastReviewDate: 2021-10-20

author: Computable Publishing®: MEDLINE-to-FEvIR Converter:

classification

type: Citation Source (Citation Classification Type#citation-source)

classifier: MEDLINE ()

classification

type: MEDLINE Citation Owner (Citation Classification Type#medline-owner)

classifier: National Library of Medicine, Index Section (elements_descriptions.html#owner_value#NLM)

currentState: Medline Citation Status of Medline (Citation Status Type#medline-medline), PubMed PublicationStatus of ppublish (Citation Status Type#pubmed-publication-status-ppublish)

statusDate

activity: PubMed Pubstatus of Received (Citation Status Type#pubmed-pubstatus-received)

period: ?? --> 2007-11-22

statusDate

activity: PubMed Pubstatus of Revised (Citation Status Type#pubmed-pubstatus-revised)

period: ?? --> 2008-04-08

statusDate

activity: PubMed Pubstatus of Accepted (Citation Status Type#pubmed-pubstatus-accepted)

period: ?? --> 2008-04-09

statusDate

activity: PubMed Pubstatus of Pubmed (Citation Status Type#pubmed-pubstatus-pubmed)

period: ?? --> 2008-05-30 09:00:00+0000

statusDate

activity: PubMed Pubstatus of Medline (Citation Status Type#pubmed-pubstatus-medline)

period: ?? --> 2008-12-17 09:00:00+0000

statusDate

activity: PubMed Pubstatus of Entrez (Citation Status Type#pubmed-pubstatus-entrez)

period: ?? --> 2008-05-30 09:00:00+0000

citedArtifact

identifier: https://pubmed.ncbi.nlm.nih.gov/18508207, mid/NIHMS61453, https://www.ncbi.nlm.nih.gov/pmc//PMC2613766, https://doi.org/10.1016/j.drugalcdep.2008.04.002, pii/S0376-8716(08)00140-3

Titles

-	Type	Language	Text
*	Primary title (Title Type#primary)	English (Tags for the Identification of Languages#en)	A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal.

Abstracts

-

Text

*

**CONTEXT:** Lofexidine is an alpha-2-adrenergic receptor agonist that is approved in the United Kingdom for the treatment of opioid withdrawal symptoms. Lofexidine has been reported to have more significant effects on decreasing opioid withdrawal symptoms with less hypotension than clonidine. **OBJECTIVE:** To demonstrate that lofexidine is well tolerated and effective in the alleviation of observationally defined opioid withdrawal symptoms in opioid dependent individuals undergoing medically supervised opioid detoxification as compared to placebo. **DESIGN:** An inpatient, Phase 3, placebo-controlled, double-blind, randomized multi-site trial with three phases: (1) opioid agonist stabilization phase (days 1-3), (2) detoxification/medication or placebo phase (days 4-8), and (3) post detoxification/medication phase (days 9-11). **SUBJECTS:** Sixty-eight opioid dependent subjects were enrolled at three sites with 35 randomized to lofexidine and 33 to placebo. **MAIN OUTCOME MEASURE:** Modified Himmelsbach Opiate Withdrawal Scale (MHOWS) on study day 5 (second opioid detoxification treatment day). **RESULTS:** Due to significant findings, the study was terminated early. On the study day 5 MHOWS, subjects treated with lofexidine had significantly lower scores (equating to fewer/less severe withdrawal symptoms) than placebo subjects (least squares means 19.5+/-2.1 versus 30.9+/-2.7; p=0.0019). Lofexidine subjects had significantly better retention in treatment than placebo subjects (38.2% versus 15.2%; Log rank test p=0.01). **CONCLUSIONS:** Lofexidine is well tolerated and more efficacious than placebo for reducing opioid withdrawal symptoms in inpatients undergoing medically supervised opioid detoxification.

relatesTo

type: cites

classifier: Journal Article (Citation Artifact Classifier#D016428)

citation: Aghajanian GK. Central noradrenergic neurons: a locus for the functional interplay between alpha-2 adrenoceptors and opiate receptors. J Clin Psychiatry. 1982;43(6 Pt 2):20–24.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/6282816/

resourceReference: https://pubmed.ncbi.nlm.nih.gov/6282816

relatesTo

type: cites

classifier: Journal Article (Citation Artifact Classifier#D016428)

citation: Aghajanian GK. Tolerance of locus coeruleus neurones to morphine and suppression of withdrawal response by clonidine. Nature. 1978;276(5684):186–188.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/216919/

resourceReference: https://pubmed.ncbi.nlm.nih.gov/216919

relatesTo

type: cites

classifier: Journal Article (Citation Artifact Classifier#D016428)

citation: Aigner A, Schmidt U. Lofexidine, a new, antihypertensive imidazoline derivative. Clinical profile of action with single-drug treatment and in combination with hydrochlorothiazide. Arzneimittelforschung. 1982;32(8a):976–983.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/6890373/

resourceReference: https://pubmed.ncbi.nlm.nih.gov/6890373

relatesTo

type: cites

classifier: Journal Article (Citation Artifact Classifier#D016428)

citation: Akhurst JS. The use of lofexidine by drug dependency units in the United Kingdom. Eur Addict Res. 1999;5(1):43–49.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/10085500/

resourceReference: https://pubmed.ncbi.nlm.nih.gov/10085500

relatesTo

type: cites

classifier: Journal Article (Citation Artifact Classifier#D016428)

citation: Arnsten AF, Cai JX, Goldman-Rakic PS. The alpha-2 adrenergic agonist guanfacine improves memory in aged monkeys without sedative or hypotensive side effects: evidence for alpha-2 receptor subtypes. J. Neurosci. 1998;8(11):4287–4298.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/2903226/

resourceReference: https://pubmed.ncbi.nlm.nih.gov/2903226

relatesTo

type: cites

classifier: Journal Article (Citation Artifact Classifier#D016428)

citation: Aston-Jones G, Hirata H, Akaoka H. Local opiate withdrawal in locus coeruleus in vivo. Brain Res. 1997;765(2):331–336.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/9313908/

resourceReference: https://pubmed.ncbi.nlm.nih.gov/9313908

relatesTo

type: cites

classifier: Journal Article (Citation Artifact Classifier#D016428)

citation: Bearn J, Gossop M, Strang J. Randomised double-blind comparison of lofexidine and methadone in the in-patient treatment of opiate withdrawal. Drug Alcohol Depend. 1996;43(1–2):87–91.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/8957147/

resourceReference: https://pubmed.ncbi.nlm.nih.gov/8957147

relatesTo

type: cites

classifier: Journal Article (Citation Artifact Classifier#D016428)

citation: Bearn J, Gossop M, Strang J. Accelerated lofexidine treatment regimen compared with conventional lofexidine and methadone treatment for in-patient opiate detoxification. Drug Alcohol Depend. 1998;50:227–232.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/9649976/

resourceReference: https://pubmed.ncbi.nlm.nih.gov/9649976

relatesTo

type: cites

classifier: Journal Article (Citation Artifact Classifier#D016428)

citation: Buccafusco JJ, Marshall DC. Dorsal root lesions block the expression of morphine withdrawal elicited from the rat spinal cord. Neurosci Lett. 1985;59(3):319–324.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/4058799/

resourceReference: https://pubmed.ncbi.nlm.nih.gov/4058799

relatesTo

type: cites

classifier: Journal Article (Citation Artifact Classifier#D016428)

citation: Carnwath T, Hardman J. Randomised double-blind comparison of lofexidine and clonidine in the out-patient treatment of opiate withdrawal. Drug Alcohol Depend. 1998;50(3):251–254.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/9649979/

resourceReference: https://pubmed.ncbi.nlm.nih.gov/9649979

relatesTo

type: cites

classifier: Journal Article (Citation Artifact Classifier#D016428)

citation: Freedman JE, Aghajanian GK. Opiate and alpha 2-adrenoceptor responses of rat amygdaloid neurons: co-localization and interactions during withdrawal. J Neurosci. 1985;5(11):3016–3024.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/2997411/

resourceReference: https://pubmed.ncbi.nlm.nih.gov/2997411

relatesTo

type: cites

classifier: Journal Article (Citation Artifact Classifier#D016428)

citation: Gold MS, Pottash AC, Sweeney DR, Extein I, Annitto WJ. Opiate detoxification with lofexidine. Drug Alcohol Depend. 1981;8(4):307–315.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/7338185/

resourceReference: https://pubmed.ncbi.nlm.nih.gov/7338185

relatesTo

type: cites

classifier: Journal Article (Citation Artifact Classifier#D016428)

citation: Gonzalez G, Oliveto A, Kosten TR. Combating opiate dependence: a comparison among the available pharmacological options. Expert Opin Pharmacother. 2004;5(4):713–725.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/15102558/

resourceReference: https://pubmed.ncbi.nlm.nih.gov/15102558

relatesTo

type: cites

classifier: Journal Article (Citation Artifact Classifier#D016428)

citation: Gossop M. Clonidine and the treatment of the opiate withdrawal syndrome. Drug Alcohol Depend. 1988;21(3):253–259.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/3048954/

resourceReference: https://pubmed.ncbi.nlm.nih.gov/3048954

relatesTo

type: cites

classifier: Journal Article (Citation Artifact Classifier#D016428)

citation: Gossop M. The development of a short opiate withdrawal scale. Addict Behav. 1990;15(5):487–490.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/2248123/

resourceReference: https://pubmed.ncbi.nlm.nih.gov/2248123

relatesTo

type: cites

classifier: Journal Article (Citation Artifact Classifier#D016428)

citation: Gowing LR, Farrell M, Ali RL, White JM. Alpha 2-adrenergic agonists in opioid withdrawal. Addiction. 2002;97(1):49–58.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/11895270/

resourceReference: https://pubmed.ncbi.nlm.nih.gov/11895270

relatesTo

type: cites

classifier: Journal Article (Citation Artifact Classifier#D016428)

citation: Gowing L, Farrell M, Ali R, White J. Alpha2 adrenergic agonists for the management of opioid withdrawal. The Cochrane Database of Systematic Reviews CD002024. 2004

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/15495025/

resourceReference: https://pubmed.ncbi.nlm.nih.gov/15495025

relatesTo

type: cites

classifier: Journal Article (Citation Artifact Classifier#D016428)

citation: Handelsman L, Cochrane KJ, Aronson MJ, Ness R, Rubinstein KJ, Kanof PD. Two new rating scales for opiate withdrawal. Am J Drug Alcohol Abuse. 1987;13(3):293–308.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/3687892/

resourceReference: https://pubmed.ncbi.nlm.nih.gov/3687892

relatesTo

type: cites

classifier: Journal Article (Citation Artifact Classifier#D016428)

citation: Herman BH, Vocci F, Bridge P. The effects of NMDA receptor antagonists and nitric oxide synthase inhibitors on opioid tolerance and withdrawal: medication development issues for opiate addiction. Neuropsychopharmacology. 1995;13:269–294.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/8747752/

resourceReference: https://pubmed.ncbi.nlm.nih.gov/8747752

relatesTo

type: cites

citation: Herman BH, O'Brien CP. Clinical medications development for opiate addiction: Focus on nonopioids and opioid antagonists for the amelioration of opiate withdrawal symptoms and relapse prevention. Seminars in Neuroscience. 1997;9:158–172.

relatesTo

type: cites

classifier: Journal Article (Citation Artifact Classifier#D016428)

citation: Howells C, Allen S, Gupta J, Stillwell G, Marsden J, Farrell M. Prison based detoxification for opioid dependence: a randomised double blind controlled trial of lofexidine and methadone. Drug Alcohol Depend. 2002;67(2):169–176.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/12095666/

resourceReference: https://pubmed.ncbi.nlm.nih.gov/12095666

relatesTo

type: cites

classifier: Journal Article (Citation Artifact Classifier#D016428)

citation: Hser YI, Hoffman V, Grella CE, Anglin MD. A 33-year follow-up of narcotics addicts. Arch Gen Psychiatry. 2001;58(5):503–508.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/11343531/

resourceReference: https://pubmed.ncbi.nlm.nih.gov/11343531

relatesTo

type: cites

classifier: Journal Article (Citation Artifact Classifier#D016428)

citation: Hughes JR, Hatsukami D. Signs and symptoms of tobacco withdrawal. Arch Gen Psychiatry. 1986;43(3):289–294.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/3954551/

resourceReference: https://pubmed.ncbi.nlm.nih.gov/3954551

relatesTo

type: cites

classifier: Journal Article (Citation Artifact Classifier#D016428)

citation: Jarrott B, Louis WJ, Summers RJ. Characterization of central alpha-adrenoceptors using 3H-clonidine and its derivatives. Chest. 1983;83 Suppl 2:S339–S340.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/6129948/

resourceReference: https://pubmed.ncbi.nlm.nih.gov/6129948

relatesTo

type: cites

citation: Jasinski DR. Assessment of the abuse potentiality of morphine-like drugs (methods used in man) In: Martin WR, editor. Handbook of Experimental Pharmacology. Vol 45. Berlin: Springer-Verlag; 1977. pp. 197–258.

relatesTo

type: cites

classifier: Journal Article (Citation Artifact Classifier#D016428)

citation: Kahn A, Mumford JP, Rogers GA, Beckford H. Double-blind study of lofexidine and clonidine in the detoxification of opiate addicts in hospital. Drug Alcohol Depend. 1997;44(1):57–61.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/9031821/

resourceReference: https://pubmed.ncbi.nlm.nih.gov/9031821

relatesTo

type: cites

citation: Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York: John Wiley & Sons, Inc.; 1980.

relatesTo

type: cites

classifier: Journal Article (Citation Artifact Classifier#D016428)

citation: Kleber HD, Riordan CE, Rounsaville B, Kosten T, Charney D, Gaspari J, Hogan I, O'Connor C. Clonidine in outpatient detoxification from methadone maintenance. Arch Gen Psychiatry. 1985;42(4):391–394.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/3977557/

resourceReference: https://pubmed.ncbi.nlm.nih.gov/3977557

relatesTo

type: cites

citation: Kolb MR, Himmelsbach CK. Clinical studies of drug addiction. III. A critical review of the withdrawal treatments with method of evaluating abstinence syndromes. Amer. J. Psychiatry. 1938;94:759–797.

relatesTo

type: cites

classifier: Journal Article (Citation Artifact Classifier#D016428)

citation: Lin SK, Strang J, Su LW, Tsai CJ, Hu WH. Double-blind randomised controlled trial of lofexidine versus clonidine in the treatment of heroin withdrawal. Drug Alcohol Depend. 1997;48(2):127–133.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/9363412/

resourceReference: https://pubmed.ncbi.nlm.nih.gov/9363412

relatesTo

type: cites

classifier: Journal Article (Citation Artifact Classifier#D016428)

citation: Marjamaki A, Luomala K, Ala-Uotila S, Scheinen M. Use of recombinant human alpha 2-adrenoceptors to characterize subtype selectively of antagonist binding. Eur J Pharmacol. 1993;246(3):219–226.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/7901041/

resourceReference: https://pubmed.ncbi.nlm.nih.gov/7901041

relatesTo

type: cites

classifier: Journal Article (Citation Artifact Classifier#D016428)

citation: National Survey on Drug Use and Health. 2006. [accessed on April 10, 2008]. Availabel at: http://www.oas.samhsa.gov/nsduh/2k6nsduh/2k6Results.cfm.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/24288193/

resourceReference: https://pubmed.ncbi.nlm.nih.gov/24288193

relatesTo

type: cites

classifier: Journal Article (Citation Artifact Classifier#D016428)

citation: O’Brien PC, Fleming TR. A multiple testing procedure for clinical trails. Biometrics. 1979;35(3):549–556.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/497341/

resourceReference: https://pubmed.ncbi.nlm.nih.gov/497341

relatesTo

type: cites

citation: Office of National Drug Control Policy. Heroin Fact Sheet. 2003. [Accessed February 6, 2006]. Available at: http://www.whitehousedrugpolicy.gov/publications/factsht/heroin/index.html.

relatesTo

type: cites

classifier: Journal Article (Citation Artifact Classifier#D016428)

citation: Preston KL, Bigelow GE. Pharmacological advances in addiction treatment. Int J Addict. 1985;20(6–7):845–867.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/2867050/

resourceReference: https://pubmed.ncbi.nlm.nih.gov/2867050

relatesTo

type: cites

classifier: Journal Article (Citation Artifact Classifier#D016428)

citation: Raistrick D, West D, Finnegan O, Thistlethwaite G, Brearley R, Banbery J. A comparison of buprenorphine annd lofexidine for community opiate detoxification: results from a randomized controlled trail. Addict. 2005;100(12):1860–1867.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/16367987/

resourceReference: https://pubmed.ncbi.nlm.nih.gov/16367987

relatesTo

type: cites

classifier: Journal Article (Citation Artifact Classifier#D016428)

citation: Shearman GT, Lal H, Ursillo RC. Effectiveness of lofexidine in blocking morphine-withdrawal signs in the rat. Pharmacol Biochem Behav. 1980;12(4):573–575.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/7190295/

resourceReference: https://pubmed.ncbi.nlm.nih.gov/7190295

relatesTo

type: cites

citation: Snedecor GW, Cochran WG. Statistical Methods. Ames, IA: Iowa State University Press; 1967.

relatesTo

type: cites

citation: Substance Abuse and Mental Health Data Archive. National Household Survey on Drug Abuse (NHSDA) series. 2003. [Accessed February 6, 2006]. Available at http://www.icpsr.umich.edu/SAMHDA/ and http://webapp.icpsr.umich.edu/cocoon/SAMHDA-SERIES/00064.xml.

relatesTo

type: cites

classifier: Journal Article (Citation Artifact Classifier#D016428)

citation: Uhlen S, Wikberg JE. Delineation of three pharmacological subtypes of alpha 2-adrenoceptor in the rat kidney. Br J Pharmacol. 1991;104(3):657–6419.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/1665747/

resourceReference: https://pubmed.ncbi.nlm.nih.gov/1665747

relatesTo

type: cites

citation: Vocci FJ. Opiates and addiction. In: Sibley DR, Hanin I, Kuhar M, Skolnick P, editors. Handbook of Contemporary Neuropharmacology Volume 2. John Wiley and Sons publisher; 2007. pp. 691–705.

relatesTo

type: cites

classifier: Journal Article (Citation Artifact Classifier#D016428)

citation: Washton AM, Resnick RB, Perzel JF, Garwood J. Opiate detoxification using lofexidine. NIDA Res Monogr. 1982;41:261–263.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/6811916/

resourceReference: https://pubmed.ncbi.nlm.nih.gov/6811916

relatesTo

type: cites

classifier: Journal Article (Citation Artifact Classifier#D016428)

citation: White R, Alcorn R, Feinmann C. Two methods of community detoxification from opiates: an open-label comparison of lofexidine and buprenorphine. Drug Alcohol Depend. 2001;65(1):77–83.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/11714592/

resourceReference: https://pubmed.ncbi.nlm.nih.gov/11714592

relatesTo

type: cites

citation: Yu E, Herman BH, Miotto K, Montgomery A, Fudala PJ, Chiang CN, Fisher C, Kampman K, Dhopesh V, Cornish J, Walsh B, Davies K, Vocci F, Bridge P, Ling W, O’Brien CP. NIDA Research Monograph. Rockville: DHHS/NIH/NIDA; 1999. In-patient safety evaluation of lofexidine (alpha-2 adrenergic agonist) for opiate withdrawal; p. 227.

relatesTo

type: cites

citation: Yu E, Herman BH, Miotto K, Montgomery A, Fudala PJ, Chiang CN, Fisher C, Kampman K, Dhopesh V, Cornish J, Walsh B, Davies K, Vocci F, Bridge P, Ling W, O’Brien CP. In-patient safety evaluation of lofexidine (alpha-2 adrenergic agonist) for opiate detoxification. Drug Alcohol Depend. 2001;63:S175.

publicationForm

PublishedIns

-	Type	Identifier	Title	PublisherLocation
*	Periodical (Published In Type#D020492)	Print ISSN Type/0376-8716, ISOAbbreviation/Drug Alcohol Depend, ISSN Linking/0376-8716, Medline Title Abbreviation/Drug Alcohol Depend, NLM Unique ID/7513587	Drug and alcohol dependence	Ireland

citedMedium: Print (Cited Medium#print)

volume: 97

issue: 1-2

articleDate: 2008-09-01

publicationDateText: 2008-Sep-01

language: English (Tags for the Identification of Languages#en)

pageString: 158-68

publicationForm

citedMedium: Internet without issue (Cited Medium#internet-without-issue)

articleDate: 2008-05-27

webLocation

classifier: Abstract (Artifact Url Classifier#abstract)

url: https://pubmed.ncbi.nlm.nih.gov/18508207/

webLocation

classifier: DOI Based (Artifact Url Classifier#doi-based)

url: https://doi.org/10.1016/j.drugalcdep.2008.04.002

classification

type: Publishing Model (Cited Artifact Classification Type#publishing-model)

classifier: Print Electronic (Citation Artifact Classifier#Print-Electronic)

classification

type: Chemical (Cited Artifact Classification Type#chemical)

classifier: Adrenergic alpha-Agonists (#D000316), Analgesics, Opioid (#D000701), Clonidine (chemical-substances#MN3L5RMN02; #D003000), lofexidine (chemical-substances#UI82K0T627; #C025655)

classification

type: MeSH Heading (Cited Artifact Classification Type#mesh-heading)

artifactAssessment:

artifact: #

content

informationType: classifier

type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")

classifier: Adrenergic alpha-Agonists (#D000316)

freeToShare: true

component

type: qualifier ()

classifier: is not a major topic ()

component

type: qualifier ()

classifier: adverse effects (#Q000009)

component

component

type: qualifier ()

classifier: therapeutic use (#Q000627)

component

content

informationType: classifier

type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")

classifier: Adult (#D000328)

freeToShare: true

Components

-	Type	Classifier
*	qualifier ()	is not a major topic ()

content

informationType: classifier

type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")

classifier: Analgesics, Opioid (#D000701)

freeToShare: true

Components

-	Type	Classifier
*	qualifier ()	is Major topic ()

content

informationType: classifier

type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")

classifier: Clonidine (#D003000)

freeToShare: true

component

type: qualifier ()

classifier: is not a major topic ()

component

type: qualifier ()

classifier: adverse effects (#Q000009)

component

component

type: qualifier ()

classifier: analogs & derivatives (#Q000031)

component

component

type: qualifier ()

classifier: therapeutic use (#Q000627)

component

content

informationType: classifier

type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")

classifier: Data Collection (#D003625)

freeToShare: true

Components

-	Type	Classifier
*	qualifier ()	is not a major topic ()

content

informationType: classifier

type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")

classifier: Double-Blind Method (#D004311)

freeToShare: true

Components

-	Type	Classifier
*	qualifier ()	is not a major topic ()

content

informationType: classifier

type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")

classifier: Female (#D005260)

freeToShare: true

Components

-	Type	Classifier
*	qualifier ()	is not a major topic ()

content

informationType: classifier

type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")

classifier: Humans (#D006801)

freeToShare: true

Components

-	Type	Classifier
*	qualifier ()	is not a major topic ()

content

informationType: classifier

type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")

classifier: Male (#D008297)

freeToShare: true

Components

-	Type	Classifier
*	qualifier ()	is not a major topic ()

content

informationType: classifier

type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")

classifier: Middle Aged (#D008875)

freeToShare: true

Components

-	Type	Classifier
*	qualifier ()	is not a major topic ()

content

informationType: classifier

type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")

classifier: Psychiatric Status Rating Scales (#D011569)

freeToShare: true

Components

-	Type	Classifier
*	qualifier ()	is not a major topic ()

content

informationType: classifier

type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")

classifier: Substance Abuse Detection (#D015813)

freeToShare: true

Components

-	Type	Classifier
*	qualifier ()	is not a major topic ()

content

informationType: classifier

type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")

classifier: Substance Withdrawal Syndrome (#D013375)

freeToShare: true

component

type: qualifier ()

classifier: is not a major topic ()

component

type: qualifier ()

classifier: drug therapy (#Q000188)

component

content

informationType: classifier

type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")

classifier: Survival Analysis (#D016019)

freeToShare: true

Components

-	Type	Classifier
*	qualifier ()	is not a major topic ()

content

informationType: classifier

type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")

classifier: Treatment Outcome (#D016896)

freeToShare: true

Components

-	Type	Classifier
*	qualifier ()	is not a major topic ()

classification

type: Publication Type (Cited Artifact Classification Type#publication-type)

classifier: Clinical Trial, Phase III (#D017428), Journal Article (#D016428), Multicenter Study (#D016448), Randomized Controlled Trial (#D016449), Research Support, N.I.H., Extramural (#D052061), Research Support, U.S. Gov't, Non-P.H.S. (#D013486)

classification

type: Knowledge Artifact Type (Cited Artifact Classification Type#knowledge-artifact-type)

classifier: Journal Article (Citation Artifact Classifier#D016428)

artifactAssessment: : Classifier added by Computable Publishing LLC

classification

type: Citation Subset (Cited Artifact Classification Type#citation-subset)

classifier: IM (elements_descriptions.html#citationsubset#IM)

contributorship

complete: true

entry

contributor:

name: Elmer Yu

forenameInitials: E

affiliation: : University of Pennsylvania & Philadelphia Veterans Affairs Medical Center, Philadelphia VAMC 116, University & Woodland Avenues, Philadelphia, PA 19104, USA. yu_e@mail.trc.upenn.edu <yu_e@mail.trc.upenn.edu>

entry

contributor:

name: Karen Miotto

forenameInitials: K

entry

contributor:

name: Evaristo Akerele

forenameInitials: E

entry

contributor:

name: Ann Montgomery

forenameInitials: A

entry

contributor:

name: Ahmed Elkashef

forenameInitials: A

entry

contributor:

name: Robert Walsh

forenameInitials: R

entry

contributor:

name: Ivan Montoya

forenameInitials: I

entry

contributor:

name: Marian W Fischman

forenameInitials: MW

entry

contributor:

name: Joseph Collins

forenameInitials: J

entry

contributor:

name: Frances McSherry

forenameInitials: F

entry

contributor:

name: Kathy Boardman

forenameInitials: K

entry

contributor:

name: David K Davies

forenameInitials: DK

entry

contributor:

name: Charles P O'Brien

forenameInitials: CP

entry

contributor:

name: Walter Ling

forenameInitials: W

entry

contributor:

name: Herbert Kleber

forenameInitials: H

entry

contributor:

name: Barbara H Herman

forenameInitials: BH

Generated Narrative: Practitioner #author0

name: Elmer Yu

Generated Narrative: Practitioner #author1

name: Karen Miotto

Generated Narrative: Practitioner #author2

name: Evaristo Akerele

Generated Narrative: Practitioner #author3

name: Ann Montgomery

Generated Narrative: Practitioner #author4

name: Ahmed Elkashef

Generated Narrative: Practitioner #author5

name: Robert Walsh

Generated Narrative: Practitioner #author6

name: Ivan Montoya

Generated Narrative: Practitioner #author7

name: Marian W Fischman

Generated Narrative: Practitioner #author8

name: Joseph Collins

Generated Narrative: Practitioner #author9

name: Frances McSherry

Generated Narrative: Practitioner #author10

name: Kathy Boardman

Generated Narrative: Practitioner #author11

name: David K Davies

Generated Narrative: Practitioner #author12

name: Charles P O'Brien

Generated Narrative: Practitioner #author13

name: Walter Ling

Generated Narrative: Practitioner #author14

name: Herbert Kleber

Generated Narrative: Practitioner #author15

name: Barbara H Herman

Generated Narrative: ArtifactAssessment #meshHeading0

artifact: #

content

informationType: classifier

type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")

classifier: Adrenergic alpha-Agonists (#D000316)

freeToShare: true

component

type: qualifier ()

classifier: is not a major topic ()

component

type: qualifier ()

classifier: adverse effects (#Q000009)

component

component

type: qualifier ()

classifier: therapeutic use (#Q000627)

component

content

informationType: classifier

type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")

classifier: Adult (#D000328)

freeToShare: true

Components

-	Type	Classifier
*	qualifier ()	is not a major topic ()

content

informationType: classifier

type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")

classifier: Analgesics, Opioid (#D000701)

freeToShare: true

Components

-	Type	Classifier
*	qualifier ()	is Major topic ()

content

informationType: classifier

type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")

classifier: Clonidine (#D003000)

freeToShare: true

component

type: qualifier ()

classifier: is not a major topic ()

component

type: qualifier ()

classifier: adverse effects (#Q000009)

component

component

type: qualifier ()

classifier: analogs & derivatives (#Q000031)

component

component

type: qualifier ()

classifier: therapeutic use (#Q000627)

component

content

informationType: classifier

type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")

classifier: Data Collection (#D003625)

freeToShare: true

Components

-	Type	Classifier
*	qualifier ()	is not a major topic ()

content

informationType: classifier

type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")

classifier: Double-Blind Method (#D004311)

freeToShare: true

Components

-	Type	Classifier
*	qualifier ()	is not a major topic ()

content

informationType: classifier

type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")

classifier: Female (#D005260)

freeToShare: true

Components

-	Type	Classifier
*	qualifier ()	is not a major topic ()

content

informationType: classifier

type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")

classifier: Humans (#D006801)

freeToShare: true

Components

-	Type	Classifier
*	qualifier ()	is not a major topic ()

content

informationType: classifier

type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")

classifier: Male (#D008297)

freeToShare: true

Components

-	Type	Classifier
*	qualifier ()	is not a major topic ()

content

informationType: classifier

type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")

classifier: Middle Aged (#D008875)

freeToShare: true

Components

-	Type	Classifier
*	qualifier ()	is not a major topic ()

content

informationType: classifier

type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")

classifier: Psychiatric Status Rating Scales (#D011569)

freeToShare: true

Components

-	Type	Classifier
*	qualifier ()	is not a major topic ()

content

informationType: classifier

type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")

classifier: Substance Abuse Detection (#D015813)

freeToShare: true

Components

-	Type	Classifier
*	qualifier ()	is not a major topic ()

content

informationType: classifier

type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")

classifier: Substance Withdrawal Syndrome (#D013375)

freeToShare: true

component

type: qualifier ()

classifier: is not a major topic ()

component

type: qualifier ()

classifier: drug therapy (#Q000188)

component

content

informationType: classifier

type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")

classifier: Survival Analysis (#D016019)

freeToShare: true

Components

-	Type	Classifier
*	qualifier ()	is not a major topic ()

content

informationType: classifier

type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")

classifier: Treatment Outcome (#D016896)

freeToShare: true

Components

-	Type	Classifier
*	qualifier ()	is not a major topic ()